Philip Siberg
Chief Executive Officer
Q2 report presentation
Philip Siberg, CEO of Senzime, presented the 2025 Q2 report on July 18.
Q2 2025 report presentation
Safeguarding patients during anesthesia and recovery
Senzime develops CE and FDA-cleared precision-based patient monitoring solutions. Our products are based on 40+ years of science and developed to enhance patient safety targeting over 100 million patients globally. Senzime is listed on Nasdaq Main Market (SEZI) and cross traded in the US on the OTCQX list (SNZZF).
Press release
Senzime Awarded Contract to Supply the U.S. Department of Defense and Walter Reed National Military Medical Center
Press release
Senzime to Present at Pareto Securities’ 16th Annual Healthcare Conference
Press release
Senzime launches integration with Mindray patient monitors
Financial info April - June 2025
FIRST SIX MONTHS OF 2025: SALES INCREASED BY 90% IN LOCAL CURRENCIES
We have strong momentum. Net sales increased by 82% to SEK 49.2 million (27.0), corresponding to 90% growth in local currencies. The increase was driven by sales of next-generation TetraGraph monitors and TetraSens disposable sensors.
49,2
Net sales, TSEK
82
Net sales, % increase
64
Sales of disposable sensors, % increase
63.8
Gross margin excluding depreciation, %
Subscribe
Subscribe to our financial news to receive updates on our latest financial performance, strategic initiatives, and upcoming opportunities.